Most Popular - As we wrote in a note to PropThink Premium subscribers on Monday July 29 before the market open, an imbalance in the supply of stock … Continue Reading
Read nowLong Ideas - Shares of Alexion Pharmaceuticals (ALXN) have seen a choppy 2013 as concerns over Soliris supply and growth met rumors that Roche (RHHBY) was seeking to … Continue Reading
Read nowLong Ideas - On Thursday, July 25th, Onconova Therapeutics (ONTX) makes its debut on the NASDAQ Global Market as the 27th biotech IPO of 2013. It’s been a … Continue Reading
Read nowLong Ideas - Since making their market debut in March, shares of Enanta Pharmaceuticals (ENTA) have remained virtually flat, excluding a post-IPO pop (shares closed at $17.18 on … Continue Reading
Read nowInsights - Celsion (CLSN) has issued a glowing but arguably immaterial press release reminding investors that, yes, there is another company on earth that has a small … Continue Reading
Read nowLong Ideas - Incyte (INCY), which markets Jakafi (ruxolitinib) for the treatment of myelofibrosis, is well positioned for a strong 2nd half of 2013, as a host of … Continue Reading
Read nowLong Ideas - Update: On the morning of July 15th, Curis announced that the European Commission granted the conditional approval of Erivedge (vismodegib) for the treatment of adult patients with … Continue Reading
Read now